Prothena Stock Price, News & Analysis (NASDAQ:PRTA) $33.00 +0.52 (+1.60%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$32.65▼$33.8950-Day Range$32.31▼$52.3252-Week Range$28.51▼$79.65Volume461,543 shsAverage Volume506,983 shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$91.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Prothena MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside175.8% Upside$91.00 Price TargetShort InterestBearish11.53% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingSelling Shares$2.01 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.76) to ($4.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector443rd out of 949 stocksPharmaceutical Preparations Industry198th out of 432 stocks 3.5 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $91.00, Prothena has a forecasted upside of 175.8% from its current price of $33.00.Amount of Analyst CoverageProthena has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.53% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Prothena has recently decreased by 4.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTA. Previous Next 2.7 News and Social Media Coverage News SentimentProthena has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Prothena this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for PRTA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows2 people have added Prothena to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,005,770.00 in company stock.Percentage Held by Insiders28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from ($2.76) to ($4.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -23.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -23.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prothena Stock (NASDAQ:PRTA)Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.Read More PRTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTA Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Receives Consensus Rating of "Buy" from AnalystsNovember 18, 2023 | ca.finance.yahoo.comPRTA Dec 2023 105.000 callNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 6, 2023 | markets.businessinsider.comCantor Fitzgerald Keeps Their Buy Rating on Prothena (PRTA)November 3, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Prothena (PRTA)November 3, 2023 | finance.yahoo.comProthena (PRTA) Q3 Earnings Beat on Collaboration Revenue HikeNovember 2, 2023 | markets.businessinsider.comRudy Li’s Confidence in Prothena’s Potential: Overcoming Challenges and Delivering Strong ResultsNovember 2, 2023 | msn.comProthena (PRTA) Beats Q3 Earnings and Revenue EstimatesNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 2, 2023 | finanznachrichten.deProthena Corporation plc: Prothena Reports Third Quarter 2023 Financial Results and Business HighlightsNovember 2, 2023 | finance.yahoo.comProthena Reports Third Quarter 2023 Financial Results and Business HighlightsNovember 1, 2023 | benzinga.comEarnings Preview For Prothena CorpOctober 27, 2023 | markets.businessinsider.comProthena’s Stock Buy Rating: Potential Impact of Eisai/Biogen’s Leqembi Sub-Q Data and Implications for PRX012October 27, 2023 | markets.businessinsider.comProthena’s Stock Retains Buy Rating Amidst Adjusted Penetration Projections and Awaited Clinical Data: Tazeen Ahmad’s AnalysisOctober 26, 2023 | finanznachrichten.deProthena Corporation plc: Prothena to Report Third Quarter 2023 Financial Results on November 2October 26, 2023 | msn.comProthena, BioVie among decliners after Biogen data for new Alzheimer’s therapyOctober 26, 2023 | finance.yahoo.comProthena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 18, 2023 | finance.yahoo.com5 Biotech Stocks Set to Outpace Q3 Earnings EstimatesOctober 17, 2023 | finance.yahoo.comProthena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?October 16, 2023 | ca.investing.comProthena Corp. exploring a potential sale - BloombergOctober 16, 2023 | benzinga.comWhy Is Alzheimer's Player Prothena Stock Trading Higher Today?October 16, 2023 | reuters.comProthena prepares for potential sale - Bloomberg NewsOctober 16, 2023 | proactiveinvestors.comProthena shares buoyed by sale rumorsOctober 13, 2023 | finance.yahoo.comWe Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business GrowthOctober 12, 2023 | finance.yahoo.comInsider Sell: Brandon Smith Sells 4,000 Shares of Prothena Corp PLCOctober 6, 2023 | markets.businessinsider.comPiper Sandler Remains a Buy on Prothena (PRTA)October 5, 2023 | finance.yahoo.comInsider Sell: Chief Regulatory Officer Carol Karp Sells 5,000 Shares of Prothena Corp PLCSee More Headlines Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees127Year FoundedN/APrice Target and Rating Average Stock Price Target$91.00 High Stock Price Target$129.00 Low Stock Price Target$72.00 Potential Upside/Downside+174.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,950,000.00 Net Margins-51.92% Pretax Margin-61.37% Return on Equity-12.06% Return on Assets-9.87% Debt Debt-to-Equity RatioN/A Current Ratio12.94 Quick Ratio12.94 Sales & Book Value Annual Sales$53.90 million Price / Sales32.97 Cash FlowN/A Price / Cash FlowN/A Book Value$11.50 per share Price / Book2.88Miscellaneous Outstanding Shares53,670,000Free Float38,531,000Market Cap$1.78 billion OptionableOptionable Beta0.45 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Gene G. Kinney Ph.D. (Age 54)President, CEO & Director Comp: $1.03MMr. Tran B. Nguyen M.B.A. (Age 49)CFO & Chief Strategy Officer Comp: $762.86kMr. Brandon S. Smith (Age 48)Chief Operating Officer Comp: $756.41kMs. Carol D. Karp (Age 70)Chief Regulatory Officer Comp: $697.51kDr. Hideki Garren M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $809.59kMs. Karin L. Walker CPA (Age 60)Chief Accounting Officer & Controller Dr. Wagner M. Zago (Age 50)Chief Scientific Officer Comp: $478.79kMs. Jennifer ZibudaDirector of Investor Relations & CommunicationMr. Michael J. Malecek (Age 57)Chief Legal Officer & Company Secretary Comp: $588.25kMore ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXHarmony BiosciencesNASDAQ:HRMYPTC TherapeuticsNASDAQ:PTCTRhythm PharmaceuticalsNASDAQ:RYTMTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 2,857 shares on 11/24/2023Ownership: 0.042%Walleye Trading LLCBought 13,100 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCBought 400 shares on 11/21/2023Ownership: 0.000%Wolverine Trading LLCBought 4,300 shares on 11/16/2023Ownership: 0.000%Royal Bank of CanadaBought 290 shares on 11/15/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions PRTA Stock Analysis - Frequently Asked Questions Should I buy or sell Prothena stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRTA shares. View PRTA analyst ratings or view top-rated stocks. What is Prothena's stock price target for 2024? 7 equities research analysts have issued 1 year price objectives for Prothena's shares. Their PRTA share price targets range from $72.00 to $129.00. On average, they predict the company's share price to reach $91.00 in the next twelve months. This suggests a possible upside of 175.8% from the stock's current price. View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts. How have PRTA shares performed in 2023? Prothena's stock was trading at $60.25 on January 1st, 2023. Since then, PRTA stock has decreased by 45.2% and is now trading at $33.00. View the best growth stocks for 2023 here. When is Prothena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our PRTA earnings forecast. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.64. The biotechnology company earned $84.87 million during the quarter, compared to analysts' expectations of $51.85 million. Prothena had a negative net margin of 51.92% and a negative trailing twelve-month return on equity of 12.06%. What ETFs hold Prothena's stock? ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD). Who are Prothena's major shareholders? Prothena's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.96%), Rock Springs Capital Management LP (1.14%), Bank of New York Mellon Corp (0.93%), Northern Trust Corp (0.76%), JPMorgan Chase & Co. (0.75%) and Avidity Partners Management LP (0.71%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PRTA) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.